

Published in final edited form as:

*J Med Chem.* 2007 April 5; 50(7): 1668–1674. doi:10.1021/jm0613875.

## Stressin<sub>1</sub>-A, a Potent Corticotropin Releasing Factor Receptor 1 (CRF<sub>1</sub>)-Selective Peptide Agonist

Jean Rivier<sup>1,\*</sup>, Jozsef Gulyas<sup>1</sup>, Koichi Kunitake<sup>1</sup>, Michael DiGrucio<sup>1</sup>, Jeffrey P. Cantle<sup>1</sup>, Marilyn H. Perrin<sup>1</sup>, Cindy Donaldson<sup>1</sup>, Joan Vaughan<sup>1</sup>, Mulugeta Million<sup>2</sup>, Guillaume Gourcerol<sup>2</sup>, David W. Adelson<sup>2</sup>, Catherine Rivier<sup>1</sup>, Yvette Taché<sup>2</sup>, and Wylie Vale<sup>1</sup>

<sup>1</sup> The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, 10010 N. Torrey Pines Rd., La Jolla, CA 92037

<sup>2</sup> CURE: Digestive Diseases Research Center, and Center for Neurovisceral Sciences, VA Greater Los Angeles Healthcare System, Department of Medicine, Division of Digestive Diseases and Brain Research Institute, University of California at Los Angeles Los Angeles, CA 90073

### Abstract

The potencies and selectivity of peptide CRF antagonists is increased through structural constraints suggesting that the resulting ligands assume distinct conformations when interacting with CRF<sub>1</sub> and CRF<sub>2</sub> receptors. To develop selective CRF receptor agonists, we have scanned the sequence -Gln-Ala-His-Ser-Asn-Arg- (residues 30–35 of [DPhe<sup>12</sup>,Nle<sup>21,38</sup>]Ac-hCRF<sub>4-41</sub>) with an i-(i + 3) bridge consisting of the Glu<sup>i</sup>-Xaa-Xbb-Lys<sup>i+3</sup> scaffold where residues i = 30, 31 and 32. When i = 31 stressin<sub>1</sub>-A, a potent CRF<sub>1</sub> receptor-selective agonist was generated. *In vitro*, stressin<sub>1</sub>-A was equipotent to h/rCRF to release ACTH. Astressin<sub>1</sub>-A showed a low nanomolar affinity for CRF<sub>1</sub> receptor (K<sub>i</sub> = 1.7 nM) and greater than 100-fold selectivity versus CRF<sub>2</sub> receptor (K<sub>i</sub> = 222 nM). Stressin<sub>1</sub>-A released slightly less ACTH than oCRF in adult adrenal-intact male rats, with increased duration of action. Stressin<sub>1</sub>-A, injected intra-peritoneally, induced pellet output (a CRF<sub>1</sub> receptor-mediated response) and did not influence gastric emptying and blood pressure (CRF<sub>2</sub> receptor-mediated responses).

### Introduction

In previous reports describing the rationale used in the discovery of astressin (a potent non-selective antagonist at both CRF<sub>1</sub> and CRF<sub>2</sub> receptors) and astressin<sub>2</sub>-B (a CRF<sub>2</sub> receptor-selective antagonist), we emphasized the importance of subtle structural constraints that led to the desired compounds. Whereas a Glu<sup>30</sup>-Lys<sup>33</sup> side chain to side chain covalent lactam constraint increased affinity of linear CRF antagonists (astressin) for CRF<sub>1</sub> and CRF<sub>2</sub> receptors,<sup>2</sup> we found that a Glu<sup>32</sup>-Lys<sup>35</sup> side chain to side chain bridge in h/rCRF fragments and the corresponding Glu<sup>31</sup>-Lys<sup>34</sup> bridge in sauvagine fragments yielded potent ligands (astressin<sub>2</sub>-B) that are highly selective for the CRF<sub>2</sub> receptor.<sup>3</sup> This selectivity (>100-fold) was demonstrated using radioreceptor assays with cloned receptor cell lines and autoradiographic

\*To whom reprint requests should be addressed: Jean Rivier, Ph.D., The Salk Institute for Biological Studies, The Clayton Foundation Laboratories for Peptide Biology, 10010 N. Torrey Pines Road, La Jolla, CA 92037, 858-453-4100 ext. 1350, Fax: 858-552-1546, email: jrivier@salk.edu.

**Note:** The structure of stressin<sub>1</sub>-A was first disclosed in a Neuroscience meeting poster.<sup>1</sup> Rivier, J. E.; Gulyas, J.; Kirby, D.; Kunitake, K.; Donaldson, C. et al. Receptor-selective corticotropin releasing factor analogs. In *31st Annual Meeting of the Society for Neuroscience*: San Diego, CA, 2001; Session number 413.417.

The abbreviations for amino acids are in accord with the recommendations of the IUPAC-IUB Joint Commission on Biochemical Nomenclature (*European J. Biochem.*, 1984, 138, 9–37).

studies on rat brain slices. Additionally, we identified unique substitutions (CaMeLeu) that conferred on these antagonists long duration of action *in vivo*.<sup>4</sup>

Interestingly, extension of these sequences to full length CRF analogs yielded CRF<sub>1</sub>/CRF<sub>2</sub> receptor (astressin-derived) agonists that were only 2- to 5-fold more potent than the <sub>1</sub> parent analogues as well as agonists that had lost some of their CRF<sub>2</sub> receptor-selectivity. However, the discovery of urocortin 2 (Ucn 2)<sup>5</sup> and urocortin 3 (Ucn 3)<sup>6</sup> which are potent CRF<sub>2</sub> receptor-selective agonists provided the needed tools to study the physiological role of the CRF<sub>2</sub> receptor. Whereas a large number of studies used oCRF as a preferential CRF<sub>1</sub> receptor-selective ligand, we disclosed the structure of stressin<sub>1</sub>-A<sup>1</sup> which was equipotent to oCRF at CRF<sub>1</sub> receptor and about 4 times less potent at CRF<sub>2</sub> receptor than oCRF, resulting in a 4-fold increase in selectivity. Independently, Tezval et al. described cortagine with about 200-fold selectivity for the CRF<sub>1</sub> receptor.<sup>7</sup> Although any of these molecules may be used for the study of the pharmacological or physiological CRF<sub>1</sub>-mediated activities, we hypothesized that fragments of the most potent and selective analogue might yield a potent and CRF<sub>1</sub> receptor-selective antagonist. It is noteworthy that nonpeptide CRF<sub>1</sub> receptor-selective antagonists were available at the time of the initiation of this research, yet they are not necessarily the best tools for unraveling the physiological role of the CRF<sub>1</sub> receptor because they do not limit their action to the peripheral or central compartments. Although one would expect that peptide CRF<sub>1</sub> receptor agonists administered in the periphery would not cross the blood brain barrier, it is known that centrally administered peptides may leak to the periphery.

We disclosed the structure of stressin<sub>1</sub>-A (cyclo(31-34)[DPhe<sup>12</sup>,Nle<sup>21,38</sup>,Glu<sup>31</sup>,Lys<sup>34</sup>]Ac-hCRF<sub>(4-41)</sub>), a CRF<sub>1</sub> receptor-selective agonist, at the 31<sup>st</sup> Annual Meeting of the Society of Neuroscience held in San Diego, CA.<sup>1</sup> When it comes to nomenclature, we proposed to call CRF antagonists, astressins<sup>3</sup> and use stressins for agonists with no subscript or subscript 1 or 2 (as for the antagonists) to indicate no selectivity or selectivity for either the CRF<sub>1</sub> receptor or the CRF<sub>2</sub> receptor, respectively. The essential role of the CRF<sub>1</sub> receptor in mediating ACTH release from the pituitary in response to stress or exogenous administration of CRF or Ucn 1 is well established using CRF<sub>1</sub> receptor knockout mouse model or selective nonpeptide CRF<sub>1</sub> receptor subtype antagonists.<sup>8,9</sup> In addition, convergent *in vivo* and *in vitro* studies have emphasized the role for the CRF<sub>1</sub> receptor in stress- and peripheral administration of CRF-induced stimulation of colonic motor function (motility, transit, defecation and diarrhea).<sup>10,11</sup> In contrast, in the upper gastrointestinal tract, CRF, Ucn 1, or Ucn 2 injected peripherally, exerts an inhibitory effect on<sup>3,10,12-14</sup> gastric motility and transit that is mediated by CRF<sub>2</sub> receptors in rats and mice.

Peripheral CRF<sub>2</sub> receptors also play an important role in the modulation of cardiovascular function.<sup>15</sup> Peripheral administration of Ucn 2 induced hypotension that was blocked by the selective CRF<sub>2</sub> receptor antagonists, astressin<sub>2</sub>-B or anti-sauvagine-30 in rats.<sup>16</sup> Conversely, CRF<sub>2</sub> receptor knockout mice displayed elevated blood pressure (BP), and did not respond to peripheral injection of Ucn 1 by change in BP.<sup>17</sup> The expression of CRF<sub>2</sub>, but not CRF<sub>1</sub> receptors in the endothelial cells of arteries, further supported a direct action of urocortins within the vascular system.<sup>15,18</sup>

While selective CRF<sub>2</sub> receptor endogenous ligands, namely Ucn 2 and Ucn 3, have been characterized recently,<sup>5,6,19</sup> there is no evidence for the existence of endogenous CRF<sub>1</sub> receptor-selective ligands. Ovine CRF displays features of a preferential but not selective CRF<sub>1</sub> receptor agonist and Ucn 1 has equal affinity for both CRF receptors.<sup>19</sup> Because there is increased evidence for a modulation of CRF<sub>1</sub> receptor-mediated actions by CRF<sub>2</sub> receptors,<sup>20,21</sup> it is important to probe the CRF signaling pathways using selective CRF<sub>1</sub> receptor agonists. Here we describe some of the SAR studies that led to the discovery of stressin<sub>1</sub>-A. Additionally, we report its biological characterization in *in vitro* and *in vivo* CRF<sub>1</sub> receptor

mediated bioassays such as the release of ACTH, and the stimulation of colonic motor function along with the absence of CRF<sub>2</sub> receptor-mediated biological responses on gastric emptying and BP in rats.

## Results and Discussions

### Synthesis and physicochemical characterization

All analogues shown in Table 1 were synthesized using the solid phase method of Merrifield on a methylbenzhydrylamine resin (MBHAR) using the Boc-strategy with orthogonal protection of the side-chains of the lysine (Fmoc) and glutamic acid (OFm) residues to be cyclized.<sup>22–24</sup> Main-chain assembly was mediated in most cases by diisopropylcarbodiimide (DIC). The best results were obtained when the peptide chain was assembled in its entirety prior to cleavage of the Fmoc and OFm protecting groups and when the lactam formation was mediated by TBTU or BOP. The peptides were cleaved and deprotected in HF and purified with reversed phase high performance liquid chromatography (RPHPLC). Peptides were characterized using RPHPLC, CZE and MS (Table 1).

### Biological characterization in vitro

Selected peptides were tested in the rat dispersed anterior pituitary cell culture assay<sup>25</sup> to determine their relative potency and in cloned receptor-based assays to determine their binding affinities for two receptors (hCRF<sub>1</sub> receptor and mCRF<sub>2β</sub> receptor)<sup>26</sup> in order to determine their selectivity (Table 1). In earlier publications, we showed that deletion of the N-terminal residues (1–3)<sup>27</sup> up to (1–7)<sup>28</sup> yielded agonists with somewhat reduced relative potencies as the size of the peptide decreased. For example, whereas oCRF, Ac-oCRF and oCRF<sub>(4-41)</sub> were equipotent in the rat dispersed anterior pituitary cell culture assay, oCRF<sub>(6-41)</sub> and oCRF<sub>(7-41)</sub> had 11% and 0.5% of oCRF's potency, respectively.<sup>29</sup>

### SAR studies based on in vitro assays

The assay measuring the inhibition of CRF-stimulated release of ACTH from rat anterior pituitary cells in culture was instrumental in identifying astressin as a new lead for potent CRF antagonists because it was 32 times more potent than any of its predecessors [ $\alpha$ -hel-CRF<sub>(9-41)</sub> or [D<sup>12</sup>Phe<sup>12</sup>,Nle<sup>21,38</sup>]hCRF<sub>(12-41)</sub>].<sup>30</sup> In the same series, cyclo(26-29), cyclo(28-31) and cyclo(29-32)[D<sup>12</sup>Phe<sup>12</sup>,Glu<sup>i</sup>,Lys<sup>i+3</sup>,Nle<sup>21,38</sup>]hCRF<sub>(12-41)</sub> were ten times less potent while cyclo(24-27), cyclo(25-28), cyclo(27-30), cyclo(31-34) and cyclo(32-35) [D<sup>12</sup>Phe<sup>12</sup>,Glu<sup>i</sup>,Lys<sup>i+3</sup>,Nle<sup>21,38</sup>]hCRF<sub>(12-41)</sub> were less than 2% as potent. With the availability of receptor assays for the CRF<sub>1</sub> receptor and the CRF<sub>2</sub> receptor<sup>26</sup> and as rationalized in the introduction, the Glu<sup>i</sup>, Lys<sup>i+3</sup> cyclic lactams spanning the [D<sup>12</sup>Phe<sup>12</sup>,Nle<sup>21,38</sup>]Ac-hCRF<sub>(4-41)</sub> sequence (i = 30, 31 and 32) were tested for their affinities for the two cloned CRF receptors (Table 1). A good correlation was found between the relative *in vitro* potencies derived from the measure of ACTH stimulation in rat anterior pituitary cells in culture by increasing doses of the agonists and K<sub>i</sub> at CRF<sub>1</sub> receptor for analogues **4–9** (Table 1). Binding affinities for the CRF<sub>2</sub> receptor, however, diverged significantly from binding affinities for CRF<sub>1</sub> in the case of both linear [D<sup>12</sup>Phe<sup>12</sup>,Glu<sup>31</sup>,Lys<sup>34</sup>,Nle<sup>21,38</sup>]Ac-hCRF<sub>(4-41)</sub> (**6**) and cyclo(31-34) [D<sup>12</sup>Phe<sup>12</sup>,Glu<sup>31</sup>,Lys<sup>34</sup>,Nle<sup>21,38</sup>]Ac-hCRF<sub>(4-41)</sub> (**7**) in that they had very high affinity for the CRF<sub>1</sub> receptor and low affinity for the CRF<sub>2</sub> receptor. This was the first indication that CRF<sub>1</sub> receptor-selectivity measured by the ratio of the CRF<sub>2</sub> receptor K<sub>i</sub>/CRF<sub>1</sub> receptor K<sub>i</sub> = 93 and 130, respectively, could be modulated by the introduction of a structural constraint similar to that used to achieve CRF<sub>2</sub> receptor selectivity in astressin<sub>2</sub>-B<sup>3</sup> and consistent with that used for the potent antagonists astressin and astressin B.<sup>2,31</sup>

Although a cyclic constraint in **7** and **9** helped identify a region of the CRF molecule that could be altered to modulate selectivity towards CRF<sub>1</sub> receptor-selectivity, the fact that the

corresponding linear **6** and **8** also showed similar selectivity suggested that intramolecular (ionic) forces could also induce preferential secondary structures. Introduction of C $\alpha$ Me-leucine (C $\alpha$ MeLeu) at positions 27 and 40 was particularly beneficial (conferred long duration of action) in the cases of astressin B and astressin<sub>2</sub>-B and was well tolerated in **8** and its corresponding cyclic **9** when compared to **6** and **7** with respect to CRF<sub>1</sub> receptor-selectivity.

Because oCRF (**2**) was by itself CRF<sub>1</sub> receptor-selective, we hypothesized that the introduction of the Glu<sup>31</sup>-Xaa-Xaa-Lys<sup>34</sup> scaffold in [DPhe<sup>12</sup>,Nle<sup>21</sup>]oCRF would result in an even more CRF<sub>1</sub> receptor-selective analogue (**10**) than an analogue with the same substitution in Ac-hCRF<sub>4-41</sub> (**4**). Unexpectedly, this modification resulted in significant loss of binding affinity at CRF<sub>1</sub> receptor ( $K_i = 66$  nM) and the CRF<sub>2</sub> receptor ( $K_i > 1000$  nM). The additional C $\alpha$ MeLeu substitution of **10** to yield **11** resulted in a slight increase in CRF<sub>1</sub> receptor binding affinity in a manner similar to what was observed after C $\alpha$ Methylation of **7** to yield **9**.

Analogue **12**, resulting from the deletion of 8 residues at the N-terminus of **10**, was hypothesized to be a potential CRF<sub>1</sub> receptor-selective antagonist yet was essentially inactive in both CRF<sub>1</sub> receptor and CRF<sub>2</sub> receptor binding assays.

Shifting the i-(i+3) bridge consisting of the Glu<sup>i</sup>-Xaa-Xbb-Lys<sup>i+3</sup> scaffold in [DPhe<sup>12</sup>,Nle<sup>21,38</sup>]Ac-hCRF<sub>4-41</sub> from positions 31–34 to 32–35 restored high binding affinity at both the CRF<sub>1</sub> receptor and the CRF<sub>2</sub> receptor (**13**) and C $\alpha$ Methylation at positions 27 and 40 was well tolerated (**14**). Agonists **13** and **14** were equipotent ( $K_i = \text{ca } 1.5$  nM) at both receptors. In view of these results, we wondered whether the favorable constraints brought about by the 32–35 bridge would also favor a bioactive conformation despite further deletions at the N-terminus as we had shown for the 30–33 bridge.<sup>22</sup> Indeed, analogues derived from **14** (missing residues 1–3 from the original CRF sequence) and missing residues 1–5 (**15**), 1–6 (**16**) and 1–7 (**17**) retained considerable binding affinity, yet with decreasing relative potencies (Table 1).

While this work was in progress, and after our disclosure of the structure of stressin<sub>1</sub>-A, Tezval *et al.*<sup>7</sup> reported the synthesis and biological characterization of cortagine, [Glu<sup>21</sup>,Ala<sup>40</sup>] [Sv<sub>g</sub>1-12]<sub>x</sub>[human CRF14-30]<sub>x</sub>[Sv<sub>g</sub>30-40], a chimera derived from 2 fragments of sauvagine (residues 1–12 and 30–40) and hCRF(residues 14–30) with two substitutions: Glu<sup>21</sup> to reduce affinity to the CRF binding protein and Ala<sup>40</sup> to increase CRF<sub>1</sub> receptor selectivity. It is interesting that using two different, yet structurally based approaches, analogs of CRF were identified that showed CRF<sub>1</sub> receptor selectivity. In our assays however, we found that cortagine was equipotent (relative potency = 0.63) to oCRF (relative potency = 1.0) in the *in vitro* pituitary cell culture assay and somewhat less selective than had been reported (ratio of CRF<sub>2</sub> receptor  $K_i$ /CRF<sub>1</sub> receptor  $K_i = 200$  compared to 30 shown in Table 1)<sup>7</sup> which is not statistically different from the ratio of CRF<sub>2</sub> receptor  $K_i$ /CRF<sub>1</sub> receptor  $K_i = 43$  for oCRF. This relatively minor difference may be attributed to the fact that both compounds have very low affinity for the CRF<sub>2</sub> receptor and thus, their  $K_i$ s are not well defined.

### In vivo biological characterization

ACTH release: As shown in Figure 2, plasma ACTH levels of vehicle-injected rats remained below 80 pg/mL at all times and showed the expected circadian variations. Both CRF and stressin<sub>1</sub>-A induced significant ( $P < 0.01$ ) and dose-related increases in ACTH levels at the 10 min time point, but the pituitary response to 5.0  $\mu\text{g}$  oCRF/kg ( $1,810 \pm 239$  pg ACTH/mL) was significantly larger than that measured after 5.0  $\mu\text{g}$  stressin<sub>1</sub>-A/kg ( $752 \pm 210$  pg ACTH/mL,  $P < 0.01$ ). Animals administered 1.0 or 5.0, but not 0.2  $\mu\text{g}$  oCRF/kg still had elevated ( $P < 0.01$ ) ACTH values 1 h after injection, and these values had returned to control levels by 3 h. Stressin<sub>1</sub>-A, and **9** at 1.0 and 5.0  $\mu\text{g}/\text{kg}$  and **6** at 5.0  $\mu\text{g}/\text{kg}$  also increased ( $P < 0.01$ ) ACTH concentrations 1 h after treatment. The observation that the higher dose of the three peptides

maintained up-regulated ( $P < 0.01$ ) ACTH release at the 3 h time points suggests that their duration of action is slightly extended, compared to that of oCRF.

**Gut motor function and blood pressure**—Peptides were tested in three *in vivo* assays that are known to be mediated by either the CRF<sub>1</sub> receptor or the CRF<sub>2</sub> receptor. These are a colonic propulsive motor function test in non fasted rat, gastric emptying of non nutrient meal in an overnight fasted rat model and arterial blood pressure measure in an overnight fasted and urethane anesthetized rat model. CRF<sub>1</sub> receptor activation is well established to increase colonic transit and motility<sup>11,14</sup> while peripheral CRF<sub>2</sub> activation by CRF and related family members decreases gastric emptying<sup>10,12–14</sup> and blood pressure<sup>16</sup> in rodents. Because these activities are mediated by either one or the other CRF receptor (as shown), these measurements were critical in our evaluation of the peptides' selectivity. We found that Ucn 2, but not stressin<sub>1</sub>-A, injected ip, delayed gastric emptying in conscious rats. Stressin<sub>1</sub>-A injected ip at 10 µg/kg had no significant effect on gastric emptying of a viscous noncaloric solution in conscious rats ( $51.0 \pm 8.8\%$  compared with  $50.0 \pm 2.5\%$  in the vehicle group;  $p = 0.92$ ; Figure 2A). By contrast, ip hUcn 2 given at the same dose significantly reduced gastric emptying to  $26.4 \pm 6.9\%$  compared to both vehicle and stressin<sub>1</sub>-A groups (Figure 2A). We also found that stressin<sub>1</sub>-A injected ip stimulated colonic motor response in conscious rats. In non fasted conscious rats, stressin<sub>1</sub>-A injected ip at 10 µg/kg significantly increased the 60 min fecal pellet output when compared to saline injected rats ( $8.0 \pm 1.6$  vs.  $0.5 \pm 0.5$ /h; Figure 2B). Time course of the cumulative effects of stressin<sub>1</sub>-A on fecal pellet showed an increased response at 30 min that became significant at 45 and 60 min. In addition, stressin<sub>1</sub>-A induced diarrhea in 33% of the rats whereas none of the saline injected rats had diarrhea as monitored 60 min post injection (Figure 2B). Finally, stressin<sub>1</sub>-A, injected iv, did not modify arterial blood pressure. In urethane anesthetized rats, mean basal blood pressure was  $75.9 \pm 3.5$  mm Hg and was not significantly modified after vehicle iv injection ( $77.4 \pm 1.3$  mm Hg;  $p = 0.14$  vs. basal). Neither consecutive iv injections of stressin<sub>1</sub>-A at 3, 10 or 30 µg/kg nor of cortagine 1 at 3, 10 or 30 µg/kg produced significant changes in blood pressure compared to vehicle ( $+2.3 \pm 1.4\%$ ,  $p > 0.05$ ;  $-0.1 \pm 0.7\%$ ,  $p > 0.05$ ;  $-1.6 \pm 2\%$ ,  $p > 0.05$  for stressin<sub>1</sub>-A and  $1.4 \pm 0.8\%$ ,  $p > 0.05$ ;  $0.1 \pm 0.3\%$ ,  $p > 0.05$ ;  $-3.2 \pm 0.7\%$ ,  $p > 0.05$  for cortagine) (data not shown).

Using one *in vivo* bioassay (colonic fecal expulsion and diarrhea) in which the role of CRF<sub>1</sub> receptors has been well established to mediate the effects of peripheral injection of CRF and Ucn 1,<sup>11</sup> and two assays (decrease in gastric emptying and blood pressure changes induced by CRF or urocortins) mediated by CRF<sub>2</sub> receptor, we showed that peripheral administration of stressin<sub>1</sub>-A resulted solely in a CRF<sub>1</sub> receptor-mediated biological response. We previously reported that the CRF<sub>1</sub> receptor/CRF<sub>2</sub> receptor agonists, Ucn 1 or CRF,<sup>19</sup> injected ip at 10 µg/kg stimulated colonic transit while inhibiting gastric emptying through CRF<sub>1</sub> and CRF<sub>2</sub> receptors, respectively, in rats.<sup>14</sup> Therefore the lack of change in gastric emptying together with potent stimulation of colonic motor function induced by stressin<sub>1</sub>-A injected ip provided *in vivo* evidence for the CRF<sub>1</sub> receptor selectivity of stressin<sub>1</sub>-A. This is further corroborated by the lack of change in blood pressure when stressin<sub>1</sub>-A was injected iv and by several literature reports that emphasize the specific role of CRF<sub>2</sub> receptors in the CRF or Ucn 1-induced drop in blood pressure.<sup>3,16,17</sup>

To conclude, potent peptidic CRF<sub>2</sub> receptor agonists (urocortins 2 and 3) and antagonists (astressin<sub>2</sub>-B, anti-sauvagine-30) have been described previously. Here we report the development of stressin<sub>1</sub>-A and present *in vitro* and *in vivo* data providing convergent evidence that stressin<sub>1</sub>-A is a novel potent and selective CRF<sub>1</sub> receptor agonist that will be very useful for characterizing biological actions mediated by the CRF<sub>1</sub> receptor.<sup>32</sup> Structural studies (NMR) are presently being carried out in order to determine the conformational differences that contribute to receptor selectivity. Still missing is a potent and long acting peptide CRF<sub>1</sub> receptor antagonist to complete the panoply of peptide reagents that are critical for unraveling

the physiological roles of the CRF<sub>1</sub> receptor and the CRF<sub>2</sub> receptor, their possible inhibitory or potentiating interactions both centrally and peripherally and ultimately, their pharmacological clinical potential.

## Experimental Section

### Animals

Adult male Sprague-Dawley rats (Harlan, San Diego, CA) weighing 250–300 g were housed in group cages under controlled illumination (12:12-h light-dark cycle starting at 6 AM), humidity, and temperature (21–23°C) and had free access to tap water and Purina rat chow. Protocols were approved by the respective IACUCs of the University of California Los Angeles and Veteran Affairs Greater Los Angeles Healthcare System Animal Research Committees and the Salk Institute. When required by the experiments, rats were deprived of food but had free access to tap water for ~16 h before the experiment.

### Administration of peptides

Immediately before injection, stressin<sub>1</sub>-A was dissolved in vehicle (water or saline). Human Ucn 2 and cortagine were dissolved in water. Ip and iv injections were done respectively in 0.3 mL and in 0.1 mL.

### Rat dispersed pituitary cell culture assay

CRF analogues were tested for agonist activity in an *in vitro* assay measuring release of ACTH by collagenase dispersed rat anterior pituitary cells in culture.<sup>27,29</sup> For each *in vitro* experiment, approximately 50 anterior pituitary glands from male Sprague-Dawley rats were dissociated by collagenase treatment and plated ( $0.16 \times 10^6$  cells/well in 48-well plates) in medium containing 2% fetal bovine serum (FBS). Three days after plating, the cells were washed three times with fresh medium containing 0.1% bovine serum albumin (BSA) and incubated for 1 h. Following the 1 h pre-incubation, the cells were washed once more and the test peptides were applied in 1 mL final volume of media. At the end of a 3 h incubation period, the media were collected and 10  $\mu$ L tested for their level of ACTH using a radioimmunoassay (Nichols Institute Diagnostic).

### Cloned receptor-based binding assays

The  $K_i$  values given in Table 1 reflect the affinities of the analogues for the cloned type 1 human and type 2 $\beta$  mouse CRF receptors. The values were derived from competitive radioligand displacement assays using the non-selective <sup>125</sup>I-labeled agonist [Tyr<sup>0</sup>,Glu<sup>1</sup>,Nle<sup>17</sup>]-sauvagine as the radioligand and crude membrane fractions from CHO cells stably expressing the respective receptors.<sup>26</sup> Briefly, 200,000 cpm (ca. 0.5 nM) <sup>125</sup>I-[Tyr<sup>0</sup>,Glu<sup>1</sup>,Nle<sup>17</sup>]-sauvagine were combined with increasing concentrations of peptide (0.1 nM - 1,000 nM) in 0.2 mL assay buffer (50 mM Na HEPES, pH 7.5; 10 mM MgCl<sub>2</sub>; 2 mM EGTA; 0.1% BSA) and incubated for 90 min at 18 °C.

### Measure of gastric emptying of non nutrient meal

Gastric emptying of a non nutrient viscous meal was determined by the phenol red method as described previously in conscious over night fasted rats.<sup>33</sup> The non-caloric meal consisted of a viscous suspension of continuously stirred 1.5% methylcellulose (wt/vol) containing phenol red (50 mg/100 mL) given orogastrically through a stainless steel gavage tube (in 1.5-mL volume) to conscious rats. At 20 min after the administration of the solution, rats were euthanized by CO<sub>2</sub> inhalation. The abdominal cavity was opened, the gastroesophageal junction and the pylorus were clamped, and the stomach was isolated and rinsed in 0.9% saline. The stomach was placed into 100 mL 0.1 N NaOH and homogenized (Polytron; Brinkman

Instruments, Westbury, NY). The suspension was allowed to settle for 60 min at room temperature, then 5 mL supernatant was added to 0.5 mL of 20% trichloroacetic acid (wt/vol) and centrifuged at 3,000 rpm at 4°C for 20 min. After the supernatant was mixed with 4 mL 0.5 N NaOH, the absorbance of the sample was read at 560 nm (Shimazu 260 Spectrophotometer). The absorbance of the phenol red recovered from animals euthanized immediately after gavage of the liquid meal was taken as a standard 0% emptying. The percentage of emptying during the 20-min period was calculated with the following formula: percent emptying =  $(1 - \text{absorbance of test sample} / \text{absorbance of standard}) \times 100$ .

### Measure of colonic propulsive motor function

In non fasted conscious rats, defecation was monitored as described previously<sup>34</sup> by counting the number of fecal pellets excreted every 15 min for 1 h. The incidence of diarrhea was assessed as percent of rats that developed watery stool from the total number of treated rats.

### Measure of arterial blood pressure

Over night fasted rats were anesthetized with urethane (1.5 g/kg). Each rat was then fitted with a tracheal cannula for ventilation, a jugular vein catheter for hydration through continuous perfusion of sterile saline (0.4 mL/h) and for peptide injection, and a femoral artery catheter for BP measurement. The femoral catheter was connected to a preamplifier (model 600; Millar Instruments, Houston, TX), the output of which was subsequently amplified via a single-ended connection to the transducer amplifier. BP was acquired online at a sampling rate of 300 Hz via a Micro1401 A/D interface (Cambridge Electronic Design, Cambridge, UK) connected to a Pentium II class computer running Spike 2 (Cambridge Electronic Design) version 5 data acquisition software.

### Effect of iv oCRF and stressin<sub>1</sub>-A on ACTH release in vivo

Adrenal-intact adult (ca. 60-day-old) male Sprague-Dawley rats were implanted with iv cannulae as described earlier.<sup>20</sup> The test was conducted under minimum-stress conditions in fully awake and freely-moving animals that were not handled for either peptide injection or blood sampling. A first blood sample was obtained, immediately followed by the iv injection of the vehicle, oCRF (0.2, 1.0 or 5.0 µg/kg) or stressin<sub>1</sub>-A (1.0 or 5.0 µg/kg). Subsequently, blood samples were obtained 10 min, as well as 1, 3, 6 and 24 h later. ACTH levels were measured in plasma with an immunoradiometric assay from DiaSorin Inc. (Stillwater, MN).

### Effect of intraperitoneal hUcn 2 and stressin<sub>1</sub>-A on gastric emptying in conscious rats

Rats were deprived of food overnight but had free access to tap water for ~16 h before the experiment. Fasted rats were injected ip (0.3 mL) with saline, Ucn 2 (10 µg/kg) or stressin<sub>1</sub>-A (10 µg/kg). At 10 min after the ip injection, the phenol red methylcellulose solution was delivered through orogastric gavage (1.5 mL), and gastric emptying was determined 20 min later. Doses of peptides were based on previous dose-response studies showing a maximal response of peripheral injection of Ucn 2 on gastric emptying in rats and mice.<sup>12,14</sup>

### Effect of ip stressin<sub>1</sub>-A on colonic motor response in conscious rats

Rats were injected ip with saline or stressin<sub>1</sub>-A (10 µg/kg) and then immediately placed in individual cages to monitor the fecal pellet output and diarrhea response. These colonic responses were monitored every 15 min for 60 min after the ip injection. The dose of stressin<sub>1</sub>-A was selected on a previous dose-response study showing maximal colonic response to CRF injected ip at 10 µg/kg.<sup>14,34</sup>

### Effect of iv stressin<sub>1</sub>-A and cortagine on arterial blood pressure in anesthetized rats

Basal BP was monitored for 150 to 200 min using an acute catheter positioned into the femoral artery in urethane anesthetized rats (n = 3). Each animal received consecutive intrajugular injections of vehicle (distilled water), stressin<sub>1</sub>-A at 3, 10 and 30 µg/kg, and cortagine at 3, 10 and 30 µg/kg at 15–20 min intervals. BP was recorded throughout the studies. For each treatment, mean basal BP was recorded for 5 min before and for 2 min 30 sec after the injection. Normalized values were obtained by subtracting mean basal BP from the mean BP after injection to obtain the net BP response and dividing it by the mean basal BP, yielding the percent change from the basal state.

### Statistical analysis

All results are expressed as mean ± SEM. Comparison between multiple groups was performed by one-way ANOVA followed by Student Newman-Keuls multiple comparisons.

### Acknowledgements

This work was supported by NIH grant DK 057238 (YT), DK 026741 (JR), DK 041301 (Animal core, YT), DK 068155 (MM), VA Merit Award, and a VA Senior Career Scientist award. Dr. Gourcerol is the recipient of a French Gastroenterology Society (SNFGE) fellowship. We thank Ron Kaiser, Charleen Miller, William Low, Dr. Wolfgang Fischer, Cristin Roach, Brian Baridon and Yaira Haas for technical assistance and Mass spectrometric analysis. We thank Debbie Doan for manuscript preparation. J.R. is The Dr. Frederik Paulsen Chair in Neurosciences Professor.

### Additional abbreviations

<b>BP</b>	blood pressure
<b>BOP</b>	(benzotriazol-1-yloxy)-tris(dimethylamino)phosphonium-hexafluorophosphate
<b>BSA</b>	bovine serum albumin
<b>h/rCRF</b>	human/rat corticotropin releasing factor
<b>oCRF</b>	ovine CRF
<b>CRF<sub>1</sub></b>	CRF receptor 1
<b>CRF<sub>2</sub></b>	CRF receptor 2
<b>mCRF<sub>2</sub></b>	mouse CRF <sub>2</sub>
<b>DIC</b>	diisopropylcarbodiimide
<b>CZE</b>	capillary zone electrophoresis
<b>DCM</b>	dichloromethane




<b>DMF</b>	dimethylformamide
<b>Fmoc</b>	9-fluorenylmethoxycarbonyl
<b>HBTU</b>	<i>O</i> -(benzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
<b>HPLC</b>	high performance liquid chromatography
<b>ip</b>	intraperitoneal
<b>iv</b>	intravenously
<b>LSIMS</b>	liquid secondary ion mass spectrometry
<b>MeOH</b>	methanol
<b>MS</b>	mass spectrometry
<b>NMP</b>	<i>N</i> -methylpyrrolidone
<b>Ofm</b>	<i>O</i> -fluorenylmethyl
<b>RPHPLC</b>	reversed phase high performance liquid chromatography
<b>SAR</b>	structure activity relationships
<b>sc</b>	subcutaneous
<b>TBTU</b>	<i>O</i> -(benzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium tetrafluoroborate
<b>TEAP</b>	triethylammonium phosphate
<b>TEA</b>	triethylamine
<b>TFA</b>	trifluoroacetic acid
<b>TFE</b>	2,2,2-trifluoroethanol
<b>Xaa</b>	any amino acid


## References cited

1. Rivier, JE.; Gulyas, J.; Kirby, D.; Kunitake, K.; Donaldson, C.; Vaughan, J.; Perrin, M.; Koerber, S.; Martinez, V.; Taché, Y.; Rivier, C.; Vale, W. Receptor-selective corticotropin releasing factor analogs. 31st Annual Meeting of the Society for Neuroscience; San Diego, CA. 2001. Session number 413.417
2. Gulyas J, Rivier C, Perrin M, Koerber SC, Sutton S, Corrigan A, Lahrichi SL, Craig AG, Vale WW, Rivier J. Potent, structurally constrained agonists and competitive antagonists of corticotropin releasing factor (CRF). *Proc Natl Acad Sci USA* 1995;92:10575–10579. [PubMed: 7479843]
3. Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K, DiGruccio M, Vaughan J, Reubi JC, Waser B, Koerber SC, Martínez V, Wang LX, Taché Y, Vale W. Potent and long acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. *J Med Chem* 2002;45:4737–4747. [PubMed: 12361401]
4. Rivier JE, Kirby DA, Lahrichi SL, Corrigan A, Vale WW, Rivier CL. Constrained corticotropin releasing factor (CRF) antagonists (Astressin analogues) with long duration of action in the rat. *J Med Chem* 1999;42:3175–3182. [PubMed: 10447963]
5. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. *Proc Natl Acad Sci USA* 2001;98:2843–2848. [PubMed: 11226328]
6. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. *Proc Natl Acad Sci USA* 2001;98:7570–7575. [PubMed: 11416224]
7. Tezval H, Jahn O, Todorovic C, Sasse A, Eckart K, Spiess J. Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. *Proc Natl Acad Sci USA* 2004;101:9468–9473. [PubMed: 15192151]
8. Turnbull AV, Rivier C. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein and related peptides. *Proc Soc Exper Biol Med* 1997;215:1–10. [PubMed: 9142133]
9. Bale, T.; Vale, W. Annual Review of Pharmacology and Toxicology: Annual Reviews. 2004. CRF and CRF receptors: Role in stress responsivity and other behaviors; p. 525-557.
10. Taché Y, Perdue MH. Role of peripheral CRF signaling pathways in stress-related alterations of gut motility and mucosal function. *Neurogastroenterol Mot* 2004;16(Suppl 1):1–6.
11. Taché Y, Martinez V, Wang L, Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. *Br J Pharmacol* 2004;141:1321–1330. [PubMed: 15100165]
12. Martínez V, Wang L, Rivier JE, Vale W, Taché Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: Role of CRF receptor subtypes 1 and 2. *J Pharmacol Exper Ther* 2002;301:611–617. [PubMed: 11961064]
13. Wang LX, Martínez V, Rivier JE, Taché Y. Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2. *Am J Physiol -Regul Integ Comp Physiol* 2001;281:R1401–R1410.
14. Million M, Maillot C, Saunders P, Rivier J, Vale W, Taché Y. Human urocortin II, a new CRF-related peptide, displays selective CRF<sub>2</sub>-mediated action on gastric transit in rats. *Am J Physiol - Gastrointest Liver Physiol* 2002;282:G34–G40. [PubMed: 11751155]
15. Coste SC, Quintos RF, Stenzel-Poore MP. Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress. *Trends Cardiovasc Med* 2002;12:176–182. [PubMed: 12069758]
16. Chen C-Y, Doong M-L, Rivier JE, Taché Y. Intravenous urocortin II decreases blood pressure through CRF2 receptor in rats. *Regul Pept* 2003;113:125–130. [PubMed: 12686471]
17. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel P, Stenzel-Poore MP. Abnormal adaptations to stress and impaired cardiovascular function in mice

- lacking corticotropin-releasing hormone receptor-2. *Nat Genet* 2000;24:403–409. [PubMed: 10742107]
18. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. *Br J Pharmacol* 2004;143:508–514. [PubMed: 15381637]
  19. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. *Pharmacol Rev* 2003;55:21–26. [PubMed: 12615952]
  20. Rivier C, Grigoriadis D, Rivier J. Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat ACTH response to stressors. *Endocrinology* 2003;144:2396–2403. [PubMed: 12746300]
  21. Million M, Wang L, Wang Y, Adelson DW, Yuan P, Maillot C, Coutinho SV, McRoberts JA, Bayati A, Mattsson H, Wu VS, Wei JY, Rivier J, Vale W, Mayer EA, Taché Y. CRF2 receptor activation prevents colorectal distension-induced visceral pain and spinal ERK1/2 phosphorylation in rats. *Gut* 2006;55:172–181. [PubMed: 15985561]
  22. Rivier J, Lahrichi SL, Gulyas J, Erchegeyi J, Koerber SC, Craig AG, Corrigan A, Rivier C, Vale W. Minimal-size, constrained corticotropin releasing factor agonists with *i*-(*i*+3) Glu-Lys and Lys-Glu bridges. *J Med Chem* 1998;41:2614–2620. [PubMed: 9651165]
  23. Miranda A, Koerber SC, Gulyas J, Lahrichi S, Craig AG, Corrigan A, Hagler A, Rivier C, Vale WW, Rivier JE. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. *J Med Chem* 1994;37:1450–1459. [PubMed: 8182703]
  24. Miranda A, Lahrichi SL, Gulyas J, Koerber SC, Craig AG, Corrigan A, Rivier C, Vale WW, Rivier JE. Constrained corticotropin releasing factor (CRF) antagonists with *i*-(*i*+3) Glu---Lys bridges. *J Med Chem* 1997;40:3651–3658. [PubMed: 9357532]
  25. Grant, G.; Vale, WW. *Methods in Enzymology, Hormones and Cyclic Nucleotides*. Academic Press; New York: 1974. Pituitary receptor binding assay of hypothalamic releasing factors; p. 213-219.
  26. Perrin MH, Sutton SW, Cervini L, Rivier JE, Vale WW. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of CRF receptors. *J Pharmacol Exper Ther* 1999;288:729–734. [PubMed: 9918582]
  27. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and  $\beta$ -endorphin. *Science* 1981;213:1394–1397. [PubMed: 6267699]
  28. Cervini L, Theobald P, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser<sup>7</sup> substitutions. *J Med Chem* 1999;42:761–768. [PubMed: 10052982]
  29. Rivier J, Rivier C, Vale W. Synthetic competitive antagonists of corticotropin releasing factor: Effect on ACTH secretion in the rat. *Science* 1984;224:889–891. [PubMed: 6326264]
  30. Miranda, A.; Lahrichi, S.; Gulyas, J.; Rivier, C.; Koerber, S.; Miller, C.; Corrigan, A.; Sutton, S.; Craig, AG.; Vale, W.; Rivier, J. Competitive antagonists of the corticotropin releasing factor (CRF) scanned with an *i*-(*i*+3) Glu Lys Bridge. Fifteenth American Peptide Symposium; Nashville, TN. 1997. p. 2-164.
  31. Rivier J, Gulyas J, Corrigan A, Craig AG, Martinez V, Taché Y, Vale W, Rivier C. Astressin analogues (CRF antagonists) with extended duration of action in the rat. *J Med Chem* 1998;41:5012–5019. [PubMed: 9836619]
  32. Yuan, P.; Million, M.; Rivier, J.; Pambukchian, K.; Taché, Y. Stressin 1, A specific agonist of corticotropin releasing factor (CRF) receptor type 1 (CRF1), activates submucosal neurons in ileum and myenteric neurons in colon and stimulates colonic motor function in conscious rats. 35th Annual Meeting of the Society for Neuroscience; Abstract Viewer/Itinerary Planner: Washington, D.C.. 2005. online
  33. Nozu T, Martínez V, Rivier J, Taché Y. Peripheral urocortin delays gastric emptying: role of CRF 2 receptors. *Am J Physiol: Gastrointest Liver Physiol* 1999;39:G867–G874.
  34. Maillot C, Million M, Wei JY, Gauthier A, Taché Y. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. *Gastroenterology* 2000;119:1569–1579. [PubMed: 11113078]



**Figure 1.** Plasma ACTH levels in rats injected with the vehicle, **2** (oCRF), **6**, **7** (stressin<sub>1</sub>-A) and **9**. Each point represents the mean  $\pm$  SEM of 6–7 animals. \*\*,  $P < 0.01$  vs. vehicle.



**Figure 2.**

A = Ucn 2 (hUcn 2) but not 7 (stressin<sub>1</sub>-A) injected ip decreased gastric emptying of a viscous noncaloric meal in conscious rats. Overnight fasted rats were injected ip with saline, Ucn 2 or 7 (stressin<sub>1</sub>-A), and 10 min later gavaged with the phenol red methylcellulose solution and 20 min later gastric emptying was monitored. Each column is the mean  $\pm$  SE of 5–6 rats/group. \* $p < 0.05$  compared with both vehicle and stressin<sub>1</sub>-A groups. B = 7 injected ip stimulated colonic motor function in conscious rats. Non fasted rats were injected ip with saline or 7 (stressin<sub>1</sub>-A, 10 µg/kg) and fecal pellet output and diarrhea in conscious rats was monitored. Each column represents the mean  $\pm$  SE of 6 rat/group. The numbers on the bars are the number of rats with diarrhea over the total in a group. # $P < 0.05$  vs. saline and stressin<sub>1</sub>-A; \*  $P < 0.05$  vs. saline.

Table 1

Physical and biological properties of CRF analogues.

	Cpd Name	HPLC <sup>d1</sup>	CZE <sup>b1</sup>	MS <sup>c</sup> calc	MS <sup>c</sup> found	CRF <sub>1</sub> <sup>d</sup> (nM)	CRF <sub>2</sub> <sup>d</sup> (nM)	Relative Potency <sup>e</sup>
1	t/hCRF	>98	96	4755.5	4755.5	1.0 (0.2–4.6)	6.2 (2.0–19)	1.0
2	oCRF	99	98	4668.50	4668.5	1.0 (0.9–1.6)	52 (21–128)	1.0
3	Cortagine	96	>98	4439.35	4440.3	3.4 (2.5–4.8)	102 (46–225)	0.63 (0.37–1.1)
4	cyclo(30-35)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,Glu <sup>30</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(4,41)</sub>	97	95	4440.52	4440.4	0.7 (0.2–2.0)	1.3 (0.5–3.6)	4.3 (2.5–7.8)
5	linear[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,Glu <sup>30</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(4,41)</sub>	96	95	4458.54	4458.6	0.5 (0.2–1.3)	1.6 (1.5–1.8)	4.5 (2.7–7.6)
6	linear[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,Glu <sup>31</sup> ,Lys <sup>34</sup> ]Ac-hCRF <sub>(4,41)</sub>	98	>98	4488.54	4488.5	2.7 (2.2–3.3)	252 (114–560)	1.0 (0.47–2.3)
7	cyclo(31-34)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,Glu <sup>31</sup> ,Lys <sup>34</sup> ]Ac-hCRF <sub>(4,41)</sub> (stressin <sub>1</sub> -A)	>98	98	4470.53	4470.3	1.7 (1.1–2.6)	222 (137–361)	1.1 (0.53–2.2)
8	linear[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,MeLeu <sup>27,40</sup> ,Glu <sup>31</sup> ,Lys <sup>34</sup> ]Ac-hCRF <sub>(4,41)</sub>	>98	98	4516.57	4516.5	2.7 (0.7–10)	261 (105–654)	1.1 (0.3–5.5)
9	cyclo(31-34)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,MeLeu <sup>27,40</sup> ,Glu <sup>31</sup> ,Lys <sup>34</sup> ]Ac-hCRF <sub>(4,41)</sub>	97	94	4498.56	4498.3	0.8 (0.5–1.1)	47 (21–102)	2.2 (0.8–6.2) NP
10	cyclo(31-34)[DPhe <sup>12</sup> ,Nle <sup>21</sup> ,Glu <sup>31</sup> ,Lys <sup>34</sup> ]oCRF	98	94	4704.57	4704.55	66 (28.5–154)	>1000	
11	cyclo(31-34)[DPhe <sup>12</sup> ,Nle <sup>21</sup> ,MeLeu <sup>27</sup> ,Glu <sup>31</sup> ,Lys <sup>34</sup> ]oCRF	95	94	4718.6	4718.29	50 (18–139)	>1000	
12	cyclo(31-34)[DPhe <sup>12</sup> ,Nle <sup>21</sup> ,Lys <sup>34</sup> ]Ac-oCRF <sub>(6,41)</sub>	95	91	3895.15	3895.13	>500	>500	
13	cyclo(32-35)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,Glu <sup>32</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(4,41)</sub>	96	95	4362.45	4362.5	1.8 (0.6–5.0)	1.8 (1.2–2.7)	2.7 (1.4–5.3)
14	cyclo(32-35)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,MeLeu <sup>27,40</sup> ,Glu <sup>32</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(4,41)</sub>	95	90*	4390.48	4390.6	1.3 (0.6–2.9)	1.5 (1.0–2.2)	2.8 (1.4–5.8)
15	cyclo(32-35)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,MeLeu <sup>27,40</sup> ,Glu <sup>32</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(6,41)</sub>	>98	95*	4196.37	4196.4	3.9 (2.2–7.0)	3.0 (1.0–9.2)	6.1 (3.8–9.7)
16	cyclo(32-35)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,MeLeu <sup>27,40</sup> ,Glu <sup>32</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(6,41)</sub>	>98	90*	4083.29	4083.3	11 (8.0–15.0)	1.6 (1.1–2.4)	0.32 (0.21–0.48)
17	cyclo(32-35)[DPhe <sup>12</sup> ,Nle <sup>21,38</sup> ,MeLeu <sup>27,40</sup> ,Glu <sup>32</sup> ,Lys <sup>35</sup> ]Ac-hCRF <sub>(8,41)</sub>	>98	95*	3996.26	3996.2	15.6 (9.0–26.0)	2.0 (1.6–2.4)	0.025 (0.013–0.043)

<sup>a1</sup> Percent purity determined by HPLC using buffer system: A = TEAP (pH 2.5) and B = 60% CH<sub>3</sub>CN/40% A with a gradient slope of 1% B/min, at flow rate of 0.2 mL/min on a Vydac C18 column (0.21 × 15 cm, 5 μm particle size, 300 Å pore size). Detection at 214 nm.

<sup>b</sup> Capillary zone electrophoresis (CZE) was done using a Beckman P/ACE System 2050 or 5500. Field strength of 15 kV at 30 °C, mobile phase: 100 mM sodium phosphate (85:15, H<sub>2</sub>O:CH<sub>3</sub>CN) pH 2.50, on a Supelco P175 capillary (75 μm ID × 50 cm length).

\* CZE basic; Field strength of 13 kV at 30 °C; mobile phase: 100 mM sodium borate (85:15, H<sub>2</sub>O:CH<sub>3</sub>CN) pH 8.50, on an Agilent μSIL-FS capillary (75 μm ID × 50 cm length). Detection at 214 nm for both systems.

<sup>c</sup> The observed m/z of the monoisotope compared with the calculated [M + H]<sup>+</sup> monoisotopic mass.

<sup>d</sup> The numbers given in Table 1 reflect the inhibitory binding constants, K<sub>i</sub>, for the analogues' binding to the cloned hCRF1 and mCRF2β receptors derived from competitive radioligand displacement assays using the non-selective [<sup>125</sup>I]-labeled agonist [Tyr<sup>0</sup>,Glu<sup>1</sup>,Nle<sup>17</sup>]-sauvagine as the radioligand. K<sub>i</sub> values were calculated by PRISM software. Values in parentheses are 95% confidence limits.

<sup>e</sup> Potencies are relative to ovine CRF in the *in vitro* rat pituitary cell culture assay, with 95% confidence limits in parentheses.